Research Study

An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults With Non-Tuberculous Mycobacteria Infection
Principal Investigator 
Jeremy D. Road

Overview

Body Locations and Systems 
Lungs
ClinicalTrials.gov# 
NCT03331445
Status 
Recruiting
Study Start/End 
Nov 16, 2017 to Dec 31, 2018
Locations 
Diamond Health Care Centre
Name/Title 
Chris Miller, Assistant Professor
Phone 
778-899-0607
Email Address 
miller42@mail.ubc.ca
Purpose of Study 

Non tuberculous mycobacteria (NTM) infections in the lung are almost impossible to eradicate with conventional antibiotics. These patients have few options to treat their lung infection. It has been shown that nitric oxide was safe to be inhaled for similar cystic fibrosis patients and reduced drug resistant bacteria in the lungs. Further, research indicates that clinical isolates of NTM can be eradicated by 160ppn NO exposure in the laboratory petri dish. This is not the first time inhaled NO treatment has been used in patients with NTM (case studies). This study will provide more data to see if NO therapy can reduce the NTM bacterial load in the lungs and help the patients breath better.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.